Ignite Creation Date:
2024-05-06 @ 10:15 AM
Last Modification Date:
2024-10-26 @ 12:27 PM
Study NCT ID:
NCT03205761
Status:
COMPLETED
Last Update Posted:
2024-06-06
First Post:
2017-05-09
Brief Title:
Analysis of Olaparib Response in Patients With BRCA1 andor 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
Sponsor:
Spanish Breast Cancer Research Group
Organization:
Spanish Breast Cancer Research Group
Study Overview
Official Title:
A Phase II Clinical Trial to Analyse Olaparib Response in Patients With BRCA1 andor 2 Promoter Methylation Diagnosed of Advanced Breast Cancer COMETA-Breast Study
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COMETABreast
Brief Summary:
This is a multicenter single-arm phase II clinical trial to evaluate the efficacy and safety of olaparib in patients diagnosed of advanced triple negative breast cancer TNBC with methylation of BRCA1 andor BRCA2 promoters assessed in DNA from metastatic lesions and absence of BRCA1 and 2 germline mutations
Detailed Description:
Patients must have received at least one previous regimen in the advance disease setting and must have at least one measurable lesion that can be accurately assessed according to RECIST v11 Potential eligible patients will be screened to assess somatic s BRCA promoter methylation at an reference central laboratory Germinal g BRCA mutational status will be analyzed also centrally at Myriad Genetics GmBh laboratory unless the BRCA mutational status is already known based on a Myriad previous report Patients with a positive methylation status on at least one of the two genes and lacking of known deleterious or suspected deleterious mutations in both genes could be enrolled in the study and receive olaparib
Blood and tumor samples collected from all screened patients could be used for the biomarker analysis including the assessment of germline methylation status and gene expression levels of BRCA12 An early efficacy review will be performed after 12 evaluable patients are enrolled if at least 4 of them show tumour response additional patients will be included to complete a total of 34 patients
Blood and tumor samples collected from all screened patients could be used for the biomarker analysis including the assessment of germline methylation status and gene expression levels of BRCA12 An early efficacy review will be performed after 12 evaluable patients are enrolled if at least 4 of them show tumour response additional patients will be included to complete a total of 34 patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ESR-15-11274 | OTHER_GRANT | AstraZeneca | None |
| 2016-001407-23 | EUDRACT_NUMBER | None | None |